| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNISA996248229603316 |
|
|
Autore |
Symmachus Quintus Aurelius <approximately 340-402.> |
|
|
Titolo |
The letters of Symmachus . Book 1 [[electronic resource] /] / translation by Michele Renee Salzman and Michael Roberts ; general introduction and commentary by Michele Renee Salzman |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Atlanta, : Society of Biblical Literature, c2011 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (lxxii, 215 p. ) |
|
|
|
|
|
|
Collana |
|
Writings from the Greco-Roman world / Society of Biblical Literature ; ; no. 30 |
|
|
|
|
|
|
|
|
Altri autori (Persone) |
|
SalzmanMichele Renee |
RobertsMichael John <1947-> |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Authors, Latin - Correspondence - History and criticism |
Letter writing, Latin - History - To 1500 |
Authors, Latin - Correspondence - History and criticism - To 1500 |
Letter writing, Latin - History |
Languages & Literatures |
Greek & Latin Languages & Literatures |
Rome History Theodosians, 379-455 Sources |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Bibliographic Level Mode of Issuance: Monograph |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references (p. 187-199) and index. |
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910131531803321 |
|
|
Autore |
Alex Alexander A. |
|
|
Titolo |
Attrition in the pharmaceutical industry : reasons, implications, and pathways forward / / edited by Alexander Alex, C. John Harris, Dennis A. Smith |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Hoboken, New Jersey : , : Wiley, , 2016 |
|
©2016 |
|
|
|
|
|
|
|
|
|
ISBN |
|
1-118-91434-1 |
1-118-81958-6 |
1-118-81944-6 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (373 p.) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Pharmaceutical industry - Management |
Pharmaceutical industry - Capital productivity |
Industrial efficiency |
Drug development |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, |
|
|
|
|
|
|
|
|
|
|
organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton. |
|
|
|
|
|
| |